Clinical trials: Relapsed/ Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
This study is aimed to evaluate the safety, feasibility and efficacy of CAR-T cell therapy in the treatment of relapsed or refractory multiple myeloma
- Trial name
- NCT04626752
- Testing
- BCMA CAR-T, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Relapsed or Refractory Multiple Myeloma
Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
This study is a single-center, open and dose-escalation clinical study to evaluate the safety, tolerability, PK/PD characteristics and preliminary efficacy of the investigational drug O\&D-001 injection in the treatment of…
- Trial name
- NCT07369895
- Testing
- Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D
- Where
- China
- Volunteers
- 18 people
- Sponsor
- O&D BioTech Group CO., Limited
Multiple Myeloma
Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma
This is a phase I study of perifosine in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT00415064
- Testing
- Perifosine, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- AEterna Zentaris
Multiple Myeloma, Neoplasm, Plasma Cell
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
- Conditions
- Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse
- Trial name
- NCT04271644
- Testing
- BCMA CAR-T cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Multiple Myeloma
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.
- Trial name
- NCT03915184
- Testing
- zevor-cel
- Where
- 13 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Multiple Myeloma
A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
The purpose of the study is to evaluate the pharmacokinetics and safety from the mixture of daratumumab and rHuPH20 prepared immediately before administration via Subcutaneous (SC) delivery (Part 1) and CF (co-formulated…
- Trial name
- NCT02519452
- Testing
- Daratumumab Subcutaneous (SC) Administration, Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
- Where
- 12 sites in United States, Denmark and 4 more
- Volunteers
- 120 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma, Advanced Solid Tumors
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment
The purpose of this study is to characterize the single-dose pharmacokinetic (PK) parameters of ixazomib (MLN9708) in cancer participants with either normal renal function or severe renal impairment (RI), including participants…
- Trial name
- NCT01830816
- Testing
- Ixazomib
- Where
- 11 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Multiple Myeloma
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
To assess safety and tolerability, describe the dose-limiting toxicities, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a…
- Conditions
- Acute Myeloid Leukemia, Multiple Myeloma, Diffuse Large B-cell Lymphoma
- Trial name
- NCT03106428
- Testing
- MEDI7247
- Where
- 14 sites in United States, France and 1 more
- Volunteers
- 67 people
- Sponsor
- MedImmune LLC
Relapsed or Refractory Multiple Myeloma (RRMM)
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Primary Purpose Phase Ib. To determine the Maximum Tolerated Dose (MTD) and establish the Recommended Phase IIa Dose (RP2D) of Purinostat Mesylate for Injection combined with fixed-dose Pomalidomide Capsules and Dexamethasone in…
- Trial name
- NCT06484829
- Testing
- Purinostat Mesylate 4 mg/m2, Purinostat Mesylate 6 mg/m2, Purinostat Mesylate 8.4 mg/m2
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Relapsed/Refractory Multiple Myeloma
A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
The primary objectives of this study are to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and the recommended phase two dose (RPTD) of ABT-199 when…
- Trial name
- NCT01794507
- Testing
- ABT-199, bortezomib, dexamethasone
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 66 people
- Sponsor
- AbbVie
Relapse/Refractory Multiple Myeloma
Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide
- Trial name
- IMMUNICY-1 (NCT04613557)
- Testing
- CYAD-211, Endoxan, Fludara
- Where
- 5 sites in United States, Belgium
- Volunteers
- 18 people
- Sponsor
- Celyad Oncology SA
Multiple Myeloma
A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety and the tolerability of siltuximab up to 11.0 mg/kg in combination with bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01309412
- Testing
- Siltuximab
- Where
- 5 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Janssen Pharmaceutical K.K.
Multiple Myeloma
Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects with relapsed or refractory Multiple Myeloma.
- Trial name
- NCT04671251
- Testing
- AEVI-007
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- Avalo Therapeutics, Inc.
Multiple Myeloma
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to…
- Trial name
- NCT07336472
- Testing
- IBI3003
- Where
- 6 sites in United States
- Volunteers
- 360 people
- Sponsor
- Fortvita Biologics (USA)Inc.
Multiple Myeloma
Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy
The purpose of this study is to evaluate the tolerability, safety and the pharmacokinetic (PK) profile of daratumumab in Chinese participants with relapsed or refractory multiple myeloma (RRMM) who failed at least 2 prior lines…
- Trial name
- NCT02852837
- Testing
- Daratumumab
- Where
- 5 sites in China
- Volunteers
- 50 people
- Sponsor
- Janssen Research & Development, LLC
Relapsed or Refractory Multiple Myeloma
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT02099539
- Testing
- N-803
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Altor BioScience
Leukemia, Lymphoma
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00891137
- Testing
- human myeloid progenitor cells
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cellerant Therapeutics
Multiple Myeloma
A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma
This is a first in human study which will assess the safety and tolerability of a monoclonal antibody against ICAM-1 in patients with Multiple Myeloma. The tumour response rate will also be measured.
- Trial name
- NCT01025206
- Testing
- BI-505
- Where
- 7 sites in United States, Belgium and 2 more
- Volunteers
- 35 people
- Sponsor
- BioInvent International AB
Multiple Myeloma
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
This is a first in human, phase 1, multicenter, open-label study to determine the safety and tolerability of IGM-2644 as a single agent in participants with relapsed and/or refractory MM, for whom standard therapy does not exist…
- Trial name
- NCT05908396
- Testing
- IGM-2644
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- IGM Biosciences, Inc.
Relapsed/Refractory Multiple Myeloma
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
The primary objective of the study is to evaluate the safety and tolerability of KITE-585, an autologous engineered chimeric antigen receptor (CAR) T-cell product targeting a protein commonly found on myeloma cells called B-cell…
- Trial name
- NCT03318861
- Testing
- KITE-585, Cyclophosphamide, Fludarabine
- Where
- 9 sites in United States
- Volunteers
- 17 people
- Sponsor
- Kite, A Gilead Company